274 related articles for article (PubMed ID: 21853076)
21. Targeting the leukemia microenvironment.
Konopleva M; Andreeff M
Curr Drug Targets; 2007 Jun; 8(6):685-701. PubMed ID: 17584025
[TBL] [Abstract][Full Text] [Related]
22. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
Bernasconi P; Farina M; Boni M; Dambruoso I; Calvello C
Am J Hematol; 2016 May; 91(5):507-17. PubMed ID: 26822317
[TBL] [Abstract][Full Text] [Related]
23. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
[TBL] [Abstract][Full Text] [Related]
24. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
[TBL] [Abstract][Full Text] [Related]
25. Leukemia-on-a-chip: Dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche.
Ma C; Witkowski MT; Harris J; Dolgalev I; Sreeram S; Qian W; Tong J; Chen X; Aifantis I; Chen W
Sci Adv; 2020 Oct; 6(44):. PubMed ID: 33127669
[TBL] [Abstract][Full Text] [Related]
26. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
Houghton PJ; Lock R; Carol H; Morton CL; Phelps D; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gu Y; Wilson WR; Smith MA
Pediatr Blood Cancer; 2011 Sep; 57(3):443-53. PubMed ID: 21744473
[TBL] [Abstract][Full Text] [Related]
27. Targeting of mTORC1/2 by dihydroevocarpine induces cytotoxicity in acute myeloid leukemia.
Zhang S; Xiong Y; Zhang Y; Zhao H
J Cell Physiol; 2019 Aug; 234(8):13032-13041. PubMed ID: 30548613
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
[TBL] [Abstract][Full Text] [Related]
29. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
Lemoli RM; Gulati SC
Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
[TBL] [Abstract][Full Text] [Related]
30. Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.
Mao X; McManaway S; Jaiswal JK; Hong CR; Wilson WR; Hicks KO
Cancer Biol Ther; 2019; 20(9):1258-1269. PubMed ID: 31131698
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of resistance and therapeutic prospect of leukemia mediated by signaling pathway in bone marrow microenvironment.
Zhang LP; Zhang MY; Liu WJ
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6419-6428. PubMed ID: 31378880
[TBL] [Abstract][Full Text] [Related]
32. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Alonso S; Su M; Jones JW; Ganguly S; Kane MA; Jones RJ; Ghiaur G
Oncotarget; 2015 Jun; 6(17):14905-12. PubMed ID: 25915157
[TBL] [Abstract][Full Text] [Related]
33. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.
Yamamoto-Sugitani M; Kuroda J; Ashihara E; Nagoshi H; Kobayashi T; Matsumoto Y; Sasaki N; Shimura Y; Kiyota M; Nakayama R; Akaji K; Taki T; Uoshima N; Kobayashi Y; Horiike S; Maekawa T; Taniwaki M
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17468-73. PubMed ID: 21987825
[TBL] [Abstract][Full Text] [Related]
34. Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival.
Veiga JP; Costa LF; Sallan SE; Nadler LM; Cardoso AA
Exp Hematol; 2006 May; 34(5):610-21. PubMed ID: 16647567
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.
Konopleva M; Tabe Y; Zeng Z; Andreeff M
Drug Resist Updat; 2009; 12(4-5):103-13. PubMed ID: 19632887
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
[TBL] [Abstract][Full Text] [Related]
37. Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway.
Qin Y; Liu HJ; Li M; Zhai DH; Tang YH; Yang L; Qiao KL; Yang JH; Zhong WL; Zhang Q; Liu YR; Yang G; Sun T; Yang C
EBioMedicine; 2018 Dec; 38():25-36. PubMed ID: 30396856
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of live parameters of the HS-5 human bone marrow stromal cell line cocultured with the leukemia cells in hypoxia, for the studies of leukemia-stroma cross-talk.
Podszywalow-Bartnicka P; Kominek A; Wolczyk M; Kolba MD; Swatler J; Piwocka K
Cytometry A; 2018 Jul; 93(9):929-940. PubMed ID: 30247803
[TBL] [Abstract][Full Text] [Related]
39. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
[TBL] [Abstract][Full Text] [Related]
40. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
Parameswaran R; Yu M; Lyu MA; Lim M; Rosenblum MG; Groffen J; Heisterkamp N
Leukemia; 2012 Aug; 26(8):1786-96. PubMed ID: 22373785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
